Mutations of GATA2 are also identified in AML patients, with an incidence varied from 3.6% in patients with French-American-British (FAB) M5 subtype4 to 8.1–14.4% in non-selected AML patients9–11. The gene discussed is GATA2; the disease is acute myeloid leukemia.